Home
Clinical Trials
NCT03436199

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Last Updated: 2021-12-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

558 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-29

Study Completion Date

2019-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group study of ADS-5102 (amantadine) extended release capsules in MS subjects with walking impairment. The study consisted of a screening period (up to 3 weeks), a single-blind placebo run-in period (4 weeks; during which subjects were blinded to treatment), and a double-blind treatment period (12 weeks).

For at least 30 days prior to screening, all subjects were to have received a stable regimen of MS medications, both disease-modifying and symptomatic; these medications were to continue at the same doses and regimens for the duration of the subjects' participation in the study, to the extent compatible with good neurological care. Subjects were not to have used amantadine, dalfampridine, or any 4 aminopyridine or 2,4 diaminopyridine preparation within 30 days prior to screening.

Consented subjects who completed the screening period were to undergo a 4-week single-blind placebo run-in period during which they received placebo as 2 capsules once daily at bedtime.

Subjects who completed the single-blind placebo run-in period and continued to meet study eligibility criteria were randomized with equal probability to 1 of 3 treatment groups: placebo or ADS-5102 at a final dose of 137 mg/day or 274 mg/day. Study drugs were administered as 2 capsules once daily at bedtime.

Subjects were to return to the clinic for safety and efficacy assessments at Week 0 and Week 2 prior to randomization and at Weeks 4 (randomization and baseline visit), 6 (only safety), 8, 12, and 16 after randomization. In addition, telephone visits for safety assessments were conducted at Weeks 5 and 7. Subjects who withdrew from the study before Week 16 were to have an early termination visit that included safety follow-up and efficacy assessments, as appropriate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Walking Impairment Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADS-5102, 137 mg

ADS-5102, administered once daily at bedtime from Week 4 through Week 16

Group Type EXPERIMENTAL

ADS-5102, 137 mg

Intervention Type DRUG

Oral capsules

ADS-5102, 274 mg

ADS-5102, administered once daily at bedtime from Week 4 through Week 16

Group Type EXPERIMENTAL

ADS-5102, 274 mg

Intervention Type DRUG

Oral capsules

Placebo

placebo, administered once daily at bedtime from Week 4 through Week 16

Group Type OTHER

Placebo

Intervention Type OTHER

Oral capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADS-5102, 137 mg

Oral capsules

Intervention Type DRUG

ADS-5102, 274 mg

Oral capsules

Intervention Type DRUG

Placebo

Oral capsules

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ADS-5102 amantadine extended release ADS-5102 amantadine extended release

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed a current IRB-approved informed consent form
* Male or female subjects between 18 and 70 years of age, inclusive, at the time of Screening
* Confirmed diagnosis of MS according to the 2017 McDonald criteria
* Current medication regimen must be stable for at least 30 days prior to screening, and subject must be willing to continue the same dosing regimen for the duration of study participation
* Maximum Expanded Disability Status Scale (EDSS) score during screening of 6.5
* Stable physical activity level (inclusive of prescribed physical therapy) for at least 30 days prior to screening and willing to continue without change for the duration of study participation
* A score on each of two completed screening T25FW tests between 8 and 45 seconds, inclusive

Exclusion Criteria

* Documented inability to tolerate amantadine
* Clinically significant MS relapse with onset less than 30 days prior to screening
* Receipt of dalfampridine (or any 4-aminopyridine or 2,4-diaminopyridine preparation) or amantadine within 30 days prior to screening
* History of seizures within 3 years prior to screening
* History of hallucinations (visual, auditory, or any other type) within 3 years prior to screening
* History of bipolar disorder, schizophrenia, or psychosis, regardless of treatment
* For subjects with a history of major depressive disorder, the presence of active depressive symptoms that, in the opinion of the investigator, would affect the subject's ability to complete study assessments, or which would not be in the subject's best interest to participate in the study
* Presence of orthostatic hypotension at screening: a decrease in systolic blood pressure (at least 20 mm Hg) or diastolic blood pressure (at least 10 mm Hg) within 3 minutes of the subject standing up, compared to pressures obtained while sitting
* If female, is pregnant or lactating
* If a sexually active female, is not surgically sterile or at least 2 years post-menopausal, or does not agree to utilize a highly effective hormonal method of contraception (an IUD, or vasectomized male partner is also acceptable), in combination with a barrier method, from screening through at least 4 weeks after the completion of study treatment. If a sexually active male, does not agree to utilize condoms from screening through at least 4 weeks after the completion of study treatment.
* Treatment with an investigational drug or device within 30 days prior to screening
* Treatment with an investigational biologic within 6 months or 5 half-lives, whichever is longer, prior to screening

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials Director

Role: STUDY_DIRECTOR

Adamas Pharmaceuticals

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ADS-AMT-MS301

Identifier Type: -

Identifier Source: org_study_id

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Study Groups

ADS-5102, 137 mg

ADS-5102, 137 mg

ADS-5102, 274 mg

ADS-5102, 274 mg

Placebo

Placebo

Interventions

ADS-5102, 137 mg

ADS-5102, 274 mg

Placebo

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Adamas Pharmaceuticals, Inc.

Responsible Party

Principal Investigators

Clinical Trials Director

Locations

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Admas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site

Adamas Clinical Site